Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor

Oncogene

Volumn 30, Issue 1, 2011, Pages 21-31

  Liu, W ^a   Xin, H ^b   Eckert, D T ^a   Brown, J A ^a,b   Gnarra, J R ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

anaphase promoting complex cyclosome; cell cycle; Hippel Lindau protein; hypoxia; renal cell carcinoma

Indexed keywords

CYCLIN B1; UBIQUITIN PROTEIN LIGASE; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; DOWN REGULATION; HALF LIFE TIME; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION;

CARCINOMA, RENAL CELL; CELL CYCLE; CELL HYPOXIA; CYCLIN B1; DOWN-REGULATION; HELA CELLS; HUMANS; KIDNEY NEOPLASMS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 78650984743     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.395     Document Type: Article

References (43)

1. Baker DJ, Dawlaty MM, Galardy P, van Deursen JM. (2007). Mitoticregulation of the anaphase-promoting complex. Cell Mol Life Sci 64: 589-600.
2. Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C. (2000).UMD (universal mutation database): a generic software to build and analyze locus-specific databases. Hum Mutat 15: 86-94.
3. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A et al. (2006). Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
4. de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A et al. (2001). Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 98: 1387-1392.
5. Deshaies RJ, Joazeiro CA. (2009). RING domain E3 ubiquitin ligases. Annu Rev Biochem 78: 399-434.
6. Fahling M. (2009). Cellular oxygen sensing, signalling and how to survive translational arrest in hypoxia. Acta Physiologica 195:205-230.
7. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV.(2001). Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276: 7919-7926.
8. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. (2007). HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myctranscriptional activity. Cancer Cell 11: 335-347.
9. Hackenbeck T, Knaup KX, Schietke R, Schodel J, Willam C, Wu X et al. (2009). HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent fromhypoxia. Cell Cycle 8: 1386-1395.
10. Harper JV. (2005). Synchronization of cell populations in G1/S and G2/M phases of the cell cycle. Methods Mol Biol 296:157-166.
11. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. (2003). Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5: 64-70.
12. Iliopoulos O, Kibel A, Gray S, Kaelin WG. (1995). Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
13. Iliopoulos O, Ohh M, Kaelin Jr WG. (1998). pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95: 11661-11666.
14. Jackson PK. (2004). Linking tumor suppression, DNA damage and the anaphase-promoting complex. Trends Cell Biol 14: 331-334.
15. Jung CR, Hwang KS, Yoo J, Cho WK, Kim JM, Kim WH et al.(2006). E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12: 809-816.
16. Kaelin WG. (2005). Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128.
17. Kaelin WG. (2007a). Von Hippel-Lindau disease. Annu Rev Pathol 2:145-173.
18. Kaelin Jr WG. (2007b). The von Hippel-Lindau tumor suppressorprotein and clear cell renal carcinoma. Clin Cancer Res 13:680s-684s.
19. Kaelin Jr WG. (2008). The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
20. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE.(2004). HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23: 1949-1956.
21. Lendahl U, Lee KL, Yang H, Poellinger L. (2009). Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 10: 821-832.
22. Listovsky T, Oren YS, Yudkovsky Y, Mahbubani HM, Weiss AM,Lebendiker M et al. (2004). Mammalian Cdh1/Fzr mediates its own degradation. EMBO J 23: 1619-1626.
23. Liu L, Simon MC. (2004). Regulation of transcription and translation by hypoxia. Cancer Biol Ther 3: 492-497.
24. Liu W, Li W, Fujita T, Yang Q, Wan Y. (2008). Proteolysis of CDH1 enhances susceptibility to UV radiation-induced apoptosis. Carci-nogenesis 29: 263-272.
25. Liu W, Wu G, Li W, Lobur D, Wan Y. (2007). Cdh1-anaphase-promoting complex targets Skp2 for destruction in transforming growth factor beta-induced growth inhibition. Mol Cell Biol 27: 2967-2979.
26. Musacchio A, Salmon ED. (2007). The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8: 379-393.
27. Pause A, Lee S, Lonergan KM, Klausner RD. (1998). The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95: 993-998.
28. Pfleger CM, Lee E, Kirschner MW. (2001). Substrate recognition by the Cdc20 and Cdh1 components of the anaphase-promoting complex. Genes Dev 15: 2396-2407.
29. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. (1998). Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 18: 2845-2854.
30. Schoenfeld A, Davidowitz EJ, Burk RD. (1998). A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 95: 8817-8822.
31. Semenza GL. (2009). Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 114: 2015-2019.
32. Stebbins CE, Kaelin Jr WG, Pavletich NP. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455-461.
33. Stickle NH, Cheng LS, Watson IR, Alon N, Malkin D, Irwin MS et al. (2005). Expression of p53 in renal carcinoma cells is independent of pVHL. Mut Res 578: 23-32.
34. Sudo T, Ota Y, Kotani S, Nakao M, Takami Y, Takeda S et al. (2001). Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells. EMBO J 20: 6499-6508.
35. Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H, Krek W. (2007). pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 9: 588-595.
36. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P et al. (2009). VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11: 994-1001.
37. van Leuken R, Clijsters L, Wolthuis R. (2008). To cell cycle, swing the APC/C. Biochimica et Biophysica Acta 1786: 49-59.
38. Wan Y, Liu X, Kirschner MW. (2001). The anaphase-promoting complex mediates TGF-beta signaling by targeting SnoN for destruction. Mol Cell 8: 1027-1039.
39. Warnecke C, Weidemann A, Volke M, Schietke R, Wu X, Knaup KX et al. (2008). The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res 314: 2016-2027.
40. Wasch R, Robbins JA, Cross FR. (2010). The emerging role of APC/ C(Cdh1) in controlling differentiation, genomic stability and tumor suppression. Oncogene 29: 1-10.
41. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin Jr WG. (2004). Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428: 194-198.
42. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E et al. (2004). Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 90: 1235-1243.
43. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C et al. (2008). VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 10: 361-369.